Avantika Medex Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Avantika Medex Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $972.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Avantika Medex Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $972.6K Trade | TransData Nexus

Avantika Medex Private Limited

Indian Pharmaceutical Exporter · Medical Devices & Diagnostics Specialist · $972.6K Total Trade · DGFT Verified

Avantika Medex Private Limited is an Indian pharmaceutical exporter with a total trade value of $972.6K across 2 products in 2 therapeutic categories. Based on 22 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Strip ($800.0K), Fosfomycin ($172.6K), .

Avantika Medex Private Limited — Export Portfolio & Destination Treemap

Avantika Medex Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Avantika Medex Private Limited? — Company Overview & Market Position

Avantika Medex Private Limited, established on September 18, 2007, is a privately held pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U51397GJ2007PTC082606. As of the latest available data, Avantika Medex has an authorized capital of ₹5.00 crore and a paid-up capital of ₹3.03 crore. The company is led by directors Mr. Lal Babu Singh and Mrs. Vibha Rani Singh, who have been at the helm since its inception. Avantika Medex specializes in the manufacture, export, and wholesale distribution of pharmaceutical products, serving a diverse clientele across various international markets.

What Does Avantika Medex Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Strip$800.0K 2Fosfomycin$172.6K

Avantika Medex Private Limited Therapeutic Categories — 2 Specializations

Product Portfolio — Top 2 by Export Value

Avantika Medex Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Strip	Medical Devices & Diagnostics	$800.0K	16	0.4%	11
2	Fosfomycin	Advanced Antibiotics	$172.6K	6	1.3%	5

Avantika Medex Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $972.6K. The top category is Medical Devices & Diagnostics (82.3% of portfolio), followed by Advanced Antibiotics (17.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Avantika Medex Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Avantika Medex operates a state-of-the-art manufacturing facility located at Gallops Industrial Park-2, Ahmedabad, Gujarat. This multifunctional plant, established in 2019, spans a plot area of 6,150 square meters with a built-up area of 4,055.53 square meters. The facility is EU-GMP and WHO-GMP certified, ensuring adherence to international quality standards. It is equipped with dedicated production lines for sachet filling, capsule filling, and semi-solid formulations, enabling the manufacture of a diverse range of products, including tablets (uncoated, coated, chewable, dispersible, sustained release), hard gelatin capsules, dry powder for sachets, and semi-solids like gels, creams, and ointments.

3Key Leadership

The leadership team at Avantika Medex is spearheaded by directors Mr. Lal Babu Singh and Mrs. Vibha Rani Singh, who have been instrumental in the company's growth and strategic direction since its establishment in 2007. Their combined experience and vision have been pivotal in positioning Avantika Medex as a reputable player in the pharmaceutical export sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Avantika Medex Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Avantika Medex has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility holds EU-GMP and WHO-GMP certifications, which are essential for market access in these regions. While specific regulatory filings and approvals in these markets are not publicly disclosed, the certifications indicate compliance with international standards, facilitating potential market entry. The company's strategic focus on quality and compliance positions it favorably for future regulatory approvals in these regions.

2Emerging Markets

Avantika Medex has established a strong foothold in emerging markets across Africa, Latin America, and Southeast Asia. The company's products are tested in accordance with current testing requirements and comply with global norms, enhancing their appeal in these regions. Additionally, the EU-GMP and WHO-GMP certifications held by the manufacturing facility may facilitate access to markets that require such qualifications, potentially opening doors to further expansion in these emerging markets.

3Geographic Strategy

Avantika Medex Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Avantika Medex's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's EU-GMP and WHO-GMP certifications suggest a commitment to adhering to international quality standards, which is a prerequisite for FDA approvals. The absence of publicly available FDA-specific information may indicate that the company is in the process of seeking FDA approvals or has not yet pursued them.

2WHO & EU GMP

Avantika Medex's manufacturing facility holds both EU-GMP and WHO-GMP certifications, underscoring its adherence to stringent international quality standards. These certifications are critical for market access in various regions, including the European Union and countries that recognize WHO-GMP standards. The facility's compliance with these certifications reflects the company's commitment to producing high-quality pharmaceutical products that meet global norms.

3CDSCO & Indian Regulatory

Avantika Medex Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Avantika Medex operates in a competitive pharmaceutical export market, facing competition from both domestic and international companies. While specific competitors are not identified in the available data, the company's focus on obtaining EU-GMP and WHO-GMP certifications positions it favorably in the market. These certifications are recognized globally and can enhance the company's credibility and competitiveness. Additionally, Avantika Medex's strategic expansion into emerging markets may provide a competitive edge by tapping into regions with growing demand for pharmaceutical products.

2Key Differentiators

Avantika Medex's key differentiators include its EU-GMP and WHO-GMP certified manufacturing facility, which ensures adherence to international quality standards. The company's diverse product portfolio, encompassing various pharmaceutical formulations, allows it to cater to a wide range of therapeutic needs. Additionally, Avantika Medex's strategic focus on both established and emerging markets demonstrates a balanced approach to growth and risk management.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Avantika Medex Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Avantika Medex has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $973,000 USD across 22 shipments. The company's product portfolio is concentrated, with the top five products accounting for 100% of exports. This concentration indicates a focused approach to product offerings. The company's adherence to EU-GMP and WHO-GMP standards suggests reliability and a commitment to quality, which are critical indicators for importers assessing potential suppliers.

2Certifications to Verify

Importers should verify the following certifications when considering Avantika Medex as a supplier:

EU-GMP Certification: Confirms compliance with European Union Good Manufacturing Practices.

WHO-GMP Certification: Indicates adherence to World Health Organization Good Manufacturing Practices.

FDA Registration: If applicable, confirms registration with the U.S. Food and Drug Administration.

Frequently Asked Questions — Avantika Medex Private Limited

How many pharmaceutical products does Avantika Medex Private Limited export from India?

Avantika Medex Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Strip ($800.0K), Fosfomycin ($172.6K). Total export value is $972.6K.

What is Avantika Medex Private Limited's total pharmaceutical export value?

Avantika Medex Private Limited's total pharmaceutical export value is $972.6K, based on 22 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Avantika Medex Private Limited cover?

Avantika Medex Private Limited exports across 2 therapeutic categories. The largest are Medical Devices & Diagnostics (82.3%, 1 products), Advanced Antibiotics (17.7%, 1 products).

Get Full Avantika Medex Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.